An unsolved conundrum: the ideal follow-up strategy after curative surgery for colorectal cancer

Filamin A regulates EGFR/ERK/Akt signaling and�affects colorectal cancer cell growth and migration

“…Colorectal cancer (CRC) is the third-leading cause of cancer mortality in most countries, and there were an estimated 134,490 new cases and 49,190 deaths in the United States in 2015 (1,2). Although the mortality rate from CRC has declined by 3% over the past decade, 30–40% of CRC patients still develop metastases and 50% die of CRC recurrence (3). CRC, which is associated with poor prognosis, is usually diagnosed at a late stage (4–7).…”

Is early surveillance with CT scan necessary in patients with stage II/III colorectal cancer: A retrospective study

“…Progression during postoperative chemotherapy should also be regarded as a biological marker for poor prognosis, as previous study revealed, tumor progression while on chemotherapy could represent a contraindication to surgery and had only an 8% overall survival rate at 5 years . Furthermore, as mentioned by Sinclair et al , morbidity and mortality associated with reoperation, chemotherapy, and radiotherapy for recurrent disease could nullify any potential benefit of treating recurrence.…”

IGF1R and c-met as therapeutic targets for colorectal cancer

“…Long-lasting survival of colorectal cancer is associated with the stage of disease [2]. Liver metastasis is the main cause for CRC related deaths [3]. For patients who effected by metastatic colorectal, conventional treatments include, oxaliplatin, 5-fluorouracil, irinotecan and cetuximab.…”